Rebecca J Brown1, Elif A Oral2, Elaine Cochran3, David Araújo-Vilar4, David B Savage5, Alison Long6, Gregory Fine6, Taylor Salinardi6, Phillip Gorden3. 1. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. brownrebecca@niddk.nih.gov. 2. Department of Internal Medicine, University of Michigan Medical School and Health Systems, Ann Arbor, MI, USA. 3. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. 4. Department of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain. 5. The University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK. 6. Aegerion Pharmaceuticals, Cambridge, MA, USA.
Abstract
PURPOSE: The purpose of this study is to summarize the effectiveness and safety of metreleptin in patients with congenital or acquired generalized lipodystrophy. METHODS: Patients (n = 66) aged ≥6 months had lipodystrophy, low circulating leptin, and ≥1 metabolic abnormality (diabetes mellitus, insulin resistance, or hypertriglyceridemia). Metreleptin dose (once or twice daily) was titrated to a mean dose of 0.10 mg/kg/day with a maximum of 0.24 mg/kg/day. Means and changes from baseline to month 12 were assessed for glycated hemoglobin (HbA1c), fasting triglycerides (TGs), and fasting plasma glucose (FPG). Additional assessments included the proportions of patients achieving target decreases in HbA1c or fasting TGs at months 4, 12, and 36, medication changes, and estimates of liver size. Treatment-emergent adverse events (TEAEs) were recorded. RESULTS: Significant mean reductions from baseline were seen at month 12 for HbA1c (-2.2%, n = 59) and FPG (-3.0 mmol/L, n = 59) and mean percent change in fasting TGs (-32.1%, n = 57) (all p ≤ 0.001). Reductions from baseline over time in these parameters were also significant at month 36 (all p < 0.001, n = 14). At month 4, 34.8% of patients had a ≥1% reduction in HbA1c and 62.5% had a ≥30% reduction in fasting TGs; at month 12, 80% of patients had a ≥1% decrease in HbA1c or ≥30% decrease in TGs, and 66% had a decrease of ≥2% in HbA1c or ≥40% decrease in TGs. Of those on medications, 41%, 22%, and 24% discontinued insulin, oral antidiabetic medications, or lipid-lowering medications, respectively. Mean decrease in liver volume at month 12 was 33.8% (p < 0.001, n = 12). Most TEAEs were of mild/moderate severity. CONCLUSIONS: In patients with generalized lipodystrophy, long-term treatment with metreleptin was well tolerated and resulted in sustained improvements in hypertriglyceridemia, glycemic control, and liver volume.
PURPOSE: The purpose of this study is to summarize the effectiveness and safety of metreleptin in patients with congenital or acquired generalized lipodystrophy. METHODS:Patients (n = 66) aged ≥6 months had lipodystrophy, low circulating leptin, and ≥1 metabolic abnormality (diabetes mellitus, insulin resistance, or hypertriglyceridemia). Metreleptin dose (once or twice daily) was titrated to a mean dose of 0.10 mg/kg/day with a maximum of 0.24 mg/kg/day. Means and changes from baseline to month 12 were assessed for glycated hemoglobin (HbA1c), fasting triglycerides (TGs), and fasting plasma glucose (FPG). Additional assessments included the proportions of patients achieving target decreases in HbA1c or fasting TGs at months 4, 12, and 36, medication changes, and estimates of liver size. Treatment-emergent adverse events (TEAEs) were recorded. RESULTS: Significant mean reductions from baseline were seen at month 12 for HbA1c (-2.2%, n = 59) and FPG (-3.0 mmol/L, n = 59) and mean percent change in fasting TGs (-32.1%, n = 57) (all p ≤ 0.001). Reductions from baseline over time in these parameters were also significant at month 36 (all p < 0.001, n = 14). At month 4, 34.8% of patients had a ≥1% reduction in HbA1c and 62.5% had a ≥30% reduction in fasting TGs; at month 12, 80% of patients had a ≥1% decrease in HbA1c or ≥30% decrease in TGs, and 66% had a decrease of ≥2% in HbA1c or ≥40% decrease in TGs. Of those on medications, 41%, 22%, and 24% discontinued insulin, oral antidiabetic medications, or lipid-lowering medications, respectively. Mean decrease in liver volume at month 12 was 33.8% (p < 0.001, n = 12). Most TEAEs were of mild/moderate severity. CONCLUSIONS: In patients with generalized lipodystrophy, long-term treatment with metreleptin was well tolerated and resulted in sustained improvements in hypertriglyceridemia, glycemic control, and liver volume.
Authors: Michael Miller; Neil J Stone; Christie Ballantyne; Vera Bittner; Michael H Criqui; Henry N Ginsberg; Anne Carol Goldberg; William James Howard; Marc S Jacobson; Penny M Kris-Etherton; Terry A Lennie; Moshe Levi; Theodore Mazzone; Subramanian Pennathur Journal: Circulation Date: 2011-04-18 Impact factor: 29.690
Authors: Ranganath Muniyappa; Brent S Abel; Asha Asthana; Mary F Walter; Elaine K Cochran; Alan T Remaley; Monica C Skarulis; Phillip Gorden; Rebecca J Brown Journal: J Clin Lipidol Date: 2017-02-24 Impact factor: 4.766
Authors: Adrian V Hernandez; Vinay Pasupuleti; Vicente A Benites-Zapata; Priyaleela Thota; Abhishek Deshpande; Faustino R Perez-Lopez Journal: Eur J Cancer Date: 2015-11-18 Impact factor: 9.162
Authors: John D Christensen; Andreea O Lungu; Elaine Cochran; Michael T Collins; Rachel I Gafni; James C Reynolds; Kristina I Rother; Phillip Gorden; Rebecca J Brown Journal: J Clin Endocrinol Metab Date: 2014-07-29 Impact factor: 5.958
Authors: C Vatier; S Fetita; P Boudou; C Tchankou; L Deville; Jp Riveline; J Young; L Mathivon; F Travert; D Morin; J Cahen; O Lascols; F Andreelli; Y Reznik; E Mongeois; I Madelaine; Mc Vantyghem; Jf Gautier; C Vigouroux Journal: Diabetes Obes Metab Date: 2016-01-12 Impact factor: 6.577
Authors: Ho Lim Lee; Meryl A Waldman; Sungyoung Auh; James E Balow; Elaine K Cochran; Phillip Gorden; Rebecca J Brown Journal: J Clin Endocrinol Metab Date: 2019-04-16 Impact factor: 5.958
Authors: Thiago Bruder-Nascimento; Jessica L Faulkner; Stephen Haigh; Simone Kennard; Galina Antonova; Vijay S Patel; David J R Fulton; Weiqin Chen; Eric J Belin de Chantemèle Journal: Hypertension Date: 2019-10-28 Impact factor: 10.190
Authors: Elif A Oral; Phillip Gorden; Elaine Cochran; David Araújo-Vilar; David B Savage; Alison Long; Gregory Fine; Taylor Salinardi; Rebecca J Brown Journal: Endocrine Date: 2019-02-25 Impact factor: 3.633